While the pre-therapeutic levels of HMGB1 are not predictive or relevant to be used as a prognostic marker for non-small cell lung cancer (NSCLC) patients, its role as a biomarker for prediction of response to therapy has been reported [31]. The gene discussed is HMGB1; the disease is non-small cell lung carcinoma.